KemPharm Inc

NASDAQ:KMPH   4:00:00 PM EDT
4.67
-0.09 (-1.89%)
4:00:05 PM EDT: $4.67 0.00 (0.00%)
Products, Regulatory

KemPharm Announces Positive Topline Data From Phase 1 Clinical Trial Evaluating Cardiovascular Safety Of Serdexmethylphenidate (SDX)

Published: 09/28/2022 11:42 GMT
KemPharm Inc (KMPH) - Kempharm Announces Positive Topline Data From Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (sdx).
Kempharm Inc - Sdx Administered at Single Doses of 80 Mg and 200 Mg Was Well-tolerated.
Kempharm Inc - Expects to Initiate Phase 2 Clinical Trial of Kp1077 in Patients With Ih Prior to Year-end 2022.
Kempharm Inc - Expects to Initiate Second Trial in Patients With Narcolepsy in 2023.